Evaluasi Penggunaan Klorokuin Atau Oseltamivir Terhadap Fungsi Ginjal Pasien COVID- 19 di RSUP Fatmawati Jakarta Tahun 2020
##plugins.themes.academic_pro.article.sidebar##
Published
May 31, 2023
Download
Statistic
Viewed : 315 times
##plugins.themes.academic_pro.article.main##
Abstract
Coronavirus Disease2019 (COVID-19) is a new type of coronavirus (SARSCoV-2) that resembles a case of pneumonia. This virus was first discovered in Wuhan, China. In the early period of COVID-19 in March 2020 there was a significant increase in active cases and death cases in Indonesia. There is no therapeutic treatment for COVID-19, so the use of chlorouin or oseltamivir and other drugs being tested has the potential for COVID-19. The use of drugs outside of indications can cause a decrease in function in several organs of the body, especially in the kidneys because many drugs are excreted through the kidneys. The purpose of the study was to evaluate the suitability of therapy using chloroquine or oseltamivir with the standard COVID-19 Treatment Protocol and its effect on kidney function of COVID-19 patients at the inpatient installation of Fatmawati Hospital for the period March-June 2020. The research method was descriptive observational through tracing the medical records of COVID-19 patients. with the study subjects being inpatients with confirmed COVID-19 aged 18 years who received chloroquine or oseltamivir and had normal kidney function at Fatmawati Hospital. The effect of the use of chloroquine or oseltamivir using a pre and post design which will be analyzed using a paired t test to see levels before and after use on kidney function parameters. (57 patients) standard. A total of 49.56% (56 patients) who were not suitable for therapy included a mismatch of dosage and duration of administration. The results of the Wilcoxon Test analysis on the concomitant use of chloroquine or oseltamivir serum urea and creatinine levels had Asymp values. Sig. (2-tailed) < 0.05 means that the use of chloroquine or oseltamivir affects the patient's kidney function.
##plugins.themes.academic_pro.article.details##
References
1. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific brief, 09 July 2020. Who.
2. 2020;(March):1–10.
3. Satgas Penanganan COVID-19. Analisis Data COVID-19 Indonesia Update Per 03 Januari 2021. Satuan Gugus Tugas Penanganan COVID-19 Indones.
4. 2020;(January):1–174.
5. Instiaty, Sri Darmayani IGAAP, Marzuki JE, Angelia F, William, Siane A, et al. Antiviral treatment of covid-19: A clinical pharmacology narrative review.
6. Med J Indones [Internet]. 2020;29(3):332–45. Available from:
7. http://dx.doi.org/10.13181/mji.rev.204652
8. Lukito JI. Tinjauan Antivirus untuk Terapi COVID-19. 340 Cdk-286.
9. 2020;47(5):PP:342.
10. Burhan E, Dwi Susanto A, Nasution SA, Ginanjar E, Wicaksono Pitoyo C,
11. Susilo A, et al. PROTOKOL TATALAKSANA COVID-19 TIM
12. PENYUSUN Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan
13. Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter
14. Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter
15. Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). 2020.
16. Todorovic Z, Medic B, Basta-Jovanovic G, Skodric SR, Stojanovic R, Rovcanin B, et al. Acute pretreatment with chloroquine attenuates renal I/R injury in rats. PLoS One. 2014;9(3).
17. Choo D, Hossain M, Liew P, Chowdhury S, Tan J. Side effects of oseltamivir in end-stage renal failure patients. Nephrol Dial Transplant. 2011;26(7):2339– 44.
18. Kemenkes RI. Pelayanan Kefarmasian. Pedoman Interpretasi Data Klinik. Kemenkes RI. 2011;
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
20. 2020;395(10223):497–506.
21. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Jama.
22. 2020;323(13):1239.
23. WHO. Coronavirus Disease 2019 (COVID-19) World Health Situation Report - 1. WHO Indones Situat Rep. 2020;2019(March):8.
24. World Health Organization (WHO). Novel Coronavirus (2019-nCoV), Situational report. WHO Bull [Internet]. 2020;(10):1–7. Available from:
25. https://www.who.int/docs/default-source/coronaviruse/situationreports/20200130-sitrep-10-ncov.pdf?sfvrsn=d0b2e480_2
26. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36.
27. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3.
28. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9.
29. Mustafa Hellou M, Górska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis.
30. Clin Microbiol Infect [Internet]. 2020; Available from:
31. https://doi.org/10.1016/j.cmi.2020.11.002
32. Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian Ddengan Penyakit Komorbid Covid-19. J Keperawatan Silampari.
33. 2020;4(1):1689–99.
34. Kementerian Kesehatan (Kemenkes). Pemerintah Tengah Pastikan Keamanan dan Kehalalan Vaksin COVID-19. 2020 [Internet]. 2020;19–21. Available from: http://sehatnegeriku.kemkes.go.id/baca/rilismedia/20201019/5435462/pemerintah-tengah-pastikan-keamanan-dankehalalan-vaksin-covid-19/
35. Pendidikan P, Spesialis D, Klinik P, Sakit R, Sadikin H. Pemeriksaan Fungsi Ginjal. 2016;43(2):148–54.
36. PERNEFRI. Konsensus Dialisis. 2003. 21–34 p.
37. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury.
38. Vol. 2, Kidney International Supplements. Nature Publishing Group; 2012. p.
39. 1–138.
40. Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract. 2014;27(6):573–7.
41. Liu Y, He Q, Wu M. Levofloxacin-induced crystal nephropathy. Nephrology.
42. 2015;20(6):437–8.
43. Azlin E. Obat Anti Malaria. Sari Pediatr. 2016;5(4):150.
44. BPOM. Informatorium Obat Covid-19 di Indonesia. Bpom Ri. 2020. 206 p.
45. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-
46. 19. J Crit Care [Internet]. 2020;57:279–83. Available from: https://doi.org/10.1016/j.jcrc.2020.03.005
47. Dou D, Revol R, Östbye H, Wang H, Daniels R. Influenza A virus cell entry, replication, virion assembly and movement. Front Immunol. 2018;9(JUL):1–
48. 17.
49. Pengawas B, Dan O, Indonesia R. INFORMATORIUM OBAT COVID-19 DI INDONESIA.
50. Kamal MA, Brennan BJ, Subramoney V, Lien YTK, Morcos PN, Frey N, et al. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment. Clin Pharmacol Drug Dev. 2015;4(5):326–36.
51. Depkes. Peraturan Pemerintah Republik Indonesia Nomor 44 Tahun 2009 Tentang Rumah Sakit. 2009; Available from:
52. http://www.bpkp.go.id/uu/filedownload/2/26/119.bpkp
53. Kemenkes. KMK No. 1197 ttg Standar Pelayanan Farmasi Di RS.pdf. 2004.
54. Kemenkes RI. Klasifikasi Rumah Sakit. 2010;116.
55. PERMENKES RI No 269/MENKES/PER/III/2008. permenkes ri 269/MENKES/PER/III/2008. Vol. 2008, Permenkes Ri No 269/Menkes/Per/Iii/2008. 2008. p. 7.
56. Widiarta A, Safril S, Puspita R, Borneo SH, Borneo ASH. Tinjauan Kualitas Data Klinis Pasien Bedah Pada Rekam Medis Rawat Inap Di RS
57. BHAYANGKARA TK. III HOEGENG IMAM SANTOSO BANJARMASIN.
58. J Kesehat Indones. 2016;6(2).
59. Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol [Internet].
60. 2020;886(August):173451. Available from: https://doi.org/10.1016/j.ejphar.2020.173451
61. Siagian TH. Corona Dengan Discourse Network Analysis. J Kebijak Kesehat Indones. 2020;09(02):98–106.
62. Vermonte P, Wicaksono TY. Karakteristik dan Persebaran COVID-19 di Indonesia : Temuan Awal. CSIS Comment. 2020;(April):1–12.
63. Hidayati D. the Profile of Population That Confirmed Positive for Covid-19 and Died : Indonesia and Dki Jakarta Cases. J Kependud Indones.
64. 2020;2902:93–100.
65. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al.
66. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med.
67. 2020;2(8):1069–76.
68. Drager LF, Pio-Abreu A, Lopes RD, Bortolotto LA. Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic? Curr Hypertens Rep. 2020;22(6):20–5.
69. Roeroe PAL, Sedli BP, Umboh O. Faktor Risiko Terjadinya Coronavirus Disease 2019 (Covid-19) pada Penyandang Diabetes Melitus Tipe 2. e-CliniC.
70. 2021;9(1):154–60.
71. Willim HA, Ketaren I, Supit AI. Dampak Coronavirus Disease 2019 terhadap Sistem Kardiovaskular. e-CliniC. 2020;8(2):237–45.
72. Ruiz-Sánchez JG, Núñez-Gil IJ, Cuesta M, Rubio MA, Maroun-Eid C, Arroyo-Espliguero R, et al. Prognostic Impact of Hyponatremia and
73. Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis. Front Endocrinol (Lausanne). 2020;11(November):1–12.
74. Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol [Internet]. 2020;222(6):521–31. Available from:
75. https://doi.org/10.1016/j.ajog.2020.03.021
76. Isbaniah F. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Germas. 2020;0–115.
77. Qian GQ, Chen XQ, Lv DF, Ma AHY, Wang LP, Yang N Bin, et al. Duration of SARS-CoV-2 viral shedding during COVID-19 infection. Infect Dis (Auckl) [Internet]. 2020;52(7):511–2. Available from: https://doi.org/10.1080/23744235.2020.1748705
78. Villamagna AH, Gore SJ, Lewis JS, Doggett JS. The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. Front Med.
79. 2020;7(December 2020):1–8.
80. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2.
2. 2020;(March):1–10.
3. Satgas Penanganan COVID-19. Analisis Data COVID-19 Indonesia Update Per 03 Januari 2021. Satuan Gugus Tugas Penanganan COVID-19 Indones.
4. 2020;(January):1–174.
5. Instiaty, Sri Darmayani IGAAP, Marzuki JE, Angelia F, William, Siane A, et al. Antiviral treatment of covid-19: A clinical pharmacology narrative review.
6. Med J Indones [Internet]. 2020;29(3):332–45. Available from:
7. http://dx.doi.org/10.13181/mji.rev.204652
8. Lukito JI. Tinjauan Antivirus untuk Terapi COVID-19. 340 Cdk-286.
9. 2020;47(5):PP:342.
10. Burhan E, Dwi Susanto A, Nasution SA, Ginanjar E, Wicaksono Pitoyo C,
11. Susilo A, et al. PROTOKOL TATALAKSANA COVID-19 TIM
12. PENYUSUN Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan
13. Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter
14. Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter
15. Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). 2020.
16. Todorovic Z, Medic B, Basta-Jovanovic G, Skodric SR, Stojanovic R, Rovcanin B, et al. Acute pretreatment with chloroquine attenuates renal I/R injury in rats. PLoS One. 2014;9(3).
17. Choo D, Hossain M, Liew P, Chowdhury S, Tan J. Side effects of oseltamivir in end-stage renal failure patients. Nephrol Dial Transplant. 2011;26(7):2339– 44.
18. Kemenkes RI. Pelayanan Kefarmasian. Pedoman Interpretasi Data Klinik. Kemenkes RI. 2011;
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
20. 2020;395(10223):497–506.
21. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Jama.
22. 2020;323(13):1239.
23. WHO. Coronavirus Disease 2019 (COVID-19) World Health Situation Report - 1. WHO Indones Situat Rep. 2020;2019(March):8.
24. World Health Organization (WHO). Novel Coronavirus (2019-nCoV), Situational report. WHO Bull [Internet]. 2020;(10):1–7. Available from:
25. https://www.who.int/docs/default-source/coronaviruse/situationreports/20200130-sitrep-10-ncov.pdf?sfvrsn=d0b2e480_2
26. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–36.
27. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3.
28. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9.
29. Mustafa Hellou M, Górska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis.
30. Clin Microbiol Infect [Internet]. 2020; Available from:
31. https://doi.org/10.1016/j.cmi.2020.11.002
32. Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian Ddengan Penyakit Komorbid Covid-19. J Keperawatan Silampari.
33. 2020;4(1):1689–99.
34. Kementerian Kesehatan (Kemenkes). Pemerintah Tengah Pastikan Keamanan dan Kehalalan Vaksin COVID-19. 2020 [Internet]. 2020;19–21. Available from: http://sehatnegeriku.kemkes.go.id/baca/rilismedia/20201019/5435462/pemerintah-tengah-pastikan-keamanan-dankehalalan-vaksin-covid-19/
35. Pendidikan P, Spesialis D, Klinik P, Sakit R, Sadikin H. Pemeriksaan Fungsi Ginjal. 2016;43(2):148–54.
36. PERNEFRI. Konsensus Dialisis. 2003. 21–34 p.
37. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury.
38. Vol. 2, Kidney International Supplements. Nature Publishing Group; 2012. p.
39. 1–138.
40. Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract. 2014;27(6):573–7.
41. Liu Y, He Q, Wu M. Levofloxacin-induced crystal nephropathy. Nephrology.
42. 2015;20(6):437–8.
43. Azlin E. Obat Anti Malaria. Sari Pediatr. 2016;5(4):150.
44. BPOM. Informatorium Obat Covid-19 di Indonesia. Bpom Ri. 2020. 206 p.
45. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-
46. 19. J Crit Care [Internet]. 2020;57:279–83. Available from: https://doi.org/10.1016/j.jcrc.2020.03.005
47. Dou D, Revol R, Östbye H, Wang H, Daniels R. Influenza A virus cell entry, replication, virion assembly and movement. Front Immunol. 2018;9(JUL):1–
48. 17.
49. Pengawas B, Dan O, Indonesia R. INFORMATORIUM OBAT COVID-19 DI INDONESIA.
50. Kamal MA, Brennan BJ, Subramoney V, Lien YTK, Morcos PN, Frey N, et al. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment. Clin Pharmacol Drug Dev. 2015;4(5):326–36.
51. Depkes. Peraturan Pemerintah Republik Indonesia Nomor 44 Tahun 2009 Tentang Rumah Sakit. 2009; Available from:
52. http://www.bpkp.go.id/uu/filedownload/2/26/119.bpkp
53. Kemenkes. KMK No. 1197 ttg Standar Pelayanan Farmasi Di RS.pdf. 2004.
54. Kemenkes RI. Klasifikasi Rumah Sakit. 2010;116.
55. PERMENKES RI No 269/MENKES/PER/III/2008. permenkes ri 269/MENKES/PER/III/2008. Vol. 2008, Permenkes Ri No 269/Menkes/Per/Iii/2008. 2008. p. 7.
56. Widiarta A, Safril S, Puspita R, Borneo SH, Borneo ASH. Tinjauan Kualitas Data Klinis Pasien Bedah Pada Rekam Medis Rawat Inap Di RS
57. BHAYANGKARA TK. III HOEGENG IMAM SANTOSO BANJARMASIN.
58. J Kesehat Indones. 2016;6(2).
59. Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol [Internet].
60. 2020;886(August):173451. Available from: https://doi.org/10.1016/j.ejphar.2020.173451
61. Siagian TH. Corona Dengan Discourse Network Analysis. J Kebijak Kesehat Indones. 2020;09(02):98–106.
62. Vermonte P, Wicaksono TY. Karakteristik dan Persebaran COVID-19 di Indonesia : Temuan Awal. CSIS Comment. 2020;(April):1–12.
63. Hidayati D. the Profile of Population That Confirmed Positive for Covid-19 and Died : Indonesia and Dki Jakarta Cases. J Kependud Indones.
64. 2020;2902:93–100.
65. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al.
66. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med.
67. 2020;2(8):1069–76.
68. Drager LF, Pio-Abreu A, Lopes RD, Bortolotto LA. Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic? Curr Hypertens Rep. 2020;22(6):20–5.
69. Roeroe PAL, Sedli BP, Umboh O. Faktor Risiko Terjadinya Coronavirus Disease 2019 (Covid-19) pada Penyandang Diabetes Melitus Tipe 2. e-CliniC.
70. 2021;9(1):154–60.
71. Willim HA, Ketaren I, Supit AI. Dampak Coronavirus Disease 2019 terhadap Sistem Kardiovaskular. e-CliniC. 2020;8(2):237–45.
72. Ruiz-Sánchez JG, Núñez-Gil IJ, Cuesta M, Rubio MA, Maroun-Eid C, Arroyo-Espliguero R, et al. Prognostic Impact of Hyponatremia and
73. Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis. Front Endocrinol (Lausanne). 2020;11(November):1–12.
74. Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol [Internet]. 2020;222(6):521–31. Available from:
75. https://doi.org/10.1016/j.ajog.2020.03.021
76. Isbaniah F. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Germas. 2020;0–115.
77. Qian GQ, Chen XQ, Lv DF, Ma AHY, Wang LP, Yang N Bin, et al. Duration of SARS-CoV-2 viral shedding during COVID-19 infection. Infect Dis (Auckl) [Internet]. 2020;52(7):511–2. Available from: https://doi.org/10.1080/23744235.2020.1748705
78. Villamagna AH, Gore SJ, Lewis JS, Doggett JS. The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. Front Med.
79. 2020;7(December 2020):1–8.
80. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2.